| Dr Donald H Grenz, MD | |
|
401 N 9th St, Bismarck, ND 58501-4507 | |
| (701) 530-6000 | |
| (701) 530-6430 |
| Full Name | Dr Donald H Grenz |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 27 Years |
| Location | 401 N 9th St, Bismarck, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699720995 | NPI | - | NPPES |
| P00220774 | Other | ND | MEDICARE RAILROAD |
| 11258 | Medicaid | ND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 8190 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chi Health At Home | Bismarck, ND | Home health agency |
| Chi St Alexius Health | Bismarck, ND | Hospital |
| Sanford Medical Center Bismarck | Bismarck, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Innovis Health Llc | 9931298155 | 473 |
News Archive
New legislation introduced yesterday would attempt to shift Medicare reimbursement policy to reward patient health outcomes, rather than the volume of services provided, MinnPost, a nonprofit online news organization, reports. "We need to be sure to keep score," said Sen. Amy Klobuchar, D-Minn., who introduced the bill, according to MinnPost. "That means measuring outcomes and rewarding providers that deliver quality results."
Magnet hospitals had 14% lower odds of mortality in surgery patients compared with non-Magnet hospitals in a 4-state area during a 2-year period, according to a study published online October 7 in Medical Care.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
A new study by UCSF researchers concludes that media campaigns that portray the tobacco industry in a negative light and that appeal to young adults may be a powerful intervention to decrease young adult smoking.
Mammography and sonography findings help doctors identify and appropriately treat breast cancer in men, according to a study performed at the University of Texas M.D. Cancer Center in Houston, TX.
› Verified 9 days ago
| Entity Name | Mid Dakota Clinic, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275587826 PECOS PAC ID: 9638072895 Enrollment ID: O20040127001063 |
News Archive
New legislation introduced yesterday would attempt to shift Medicare reimbursement policy to reward patient health outcomes, rather than the volume of services provided, MinnPost, a nonprofit online news organization, reports. "We need to be sure to keep score," said Sen. Amy Klobuchar, D-Minn., who introduced the bill, according to MinnPost. "That means measuring outcomes and rewarding providers that deliver quality results."
Magnet hospitals had 14% lower odds of mortality in surgery patients compared with non-Magnet hospitals in a 4-state area during a 2-year period, according to a study published online October 7 in Medical Care.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
A new study by UCSF researchers concludes that media campaigns that portray the tobacco industry in a negative light and that appeal to young adults may be a powerful intervention to decrease young adult smoking.
Mammography and sonography findings help doctors identify and appropriately treat breast cancer in men, according to a study performed at the University of Texas M.D. Cancer Center in Houston, TX.
› Verified 9 days ago
| Entity Name | Innovis Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215125463 PECOS PAC ID: 9931298155 Enrollment ID: O20071211000158 |
News Archive
New legislation introduced yesterday would attempt to shift Medicare reimbursement policy to reward patient health outcomes, rather than the volume of services provided, MinnPost, a nonprofit online news organization, reports. "We need to be sure to keep score," said Sen. Amy Klobuchar, D-Minn., who introduced the bill, according to MinnPost. "That means measuring outcomes and rewarding providers that deliver quality results."
Magnet hospitals had 14% lower odds of mortality in surgery patients compared with non-Magnet hospitals in a 4-state area during a 2-year period, according to a study published online October 7 in Medical Care.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
A new study by UCSF researchers concludes that media campaigns that portray the tobacco industry in a negative light and that appeal to young adults may be a powerful intervention to decrease young adult smoking.
Mammography and sonography findings help doctors identify and appropriately treat breast cancer in men, according to a study performed at the University of Texas M.D. Cancer Center in Houston, TX.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Donald H Grenz, MD 401 N 9th St, Bismarck, ND 58501-4507 Ph: (701) 530-6000 | Dr Donald H Grenz, MD 401 N 9th St, Bismarck, ND 58501-4507 Ph: (701) 530-6000 |
News Archive
New legislation introduced yesterday would attempt to shift Medicare reimbursement policy to reward patient health outcomes, rather than the volume of services provided, MinnPost, a nonprofit online news organization, reports. "We need to be sure to keep score," said Sen. Amy Klobuchar, D-Minn., who introduced the bill, according to MinnPost. "That means measuring outcomes and rewarding providers that deliver quality results."
Magnet hospitals had 14% lower odds of mortality in surgery patients compared with non-Magnet hospitals in a 4-state area during a 2-year period, according to a study published online October 7 in Medical Care.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
A new study by UCSF researchers concludes that media campaigns that portray the tobacco industry in a negative light and that appeal to young adults may be a powerful intervention to decrease young adult smoking.
Mammography and sonography findings help doctors identify and appropriately treat breast cancer in men, according to a study performed at the University of Texas M.D. Cancer Center in Houston, TX.
› Verified 9 days ago
Dr. Ling Sing Chow, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7000 | |
Nicholas C Mahr, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 310 N 10th Street, Bismarck, ND 58501 Phone: 701-530-7500 Fax: 701-530-7484 | |
Dr. Maria Susana Castejon Welchez, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 | |
Dr. Sharmaine Habib, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-8121 | |
Agnieszka Olga Solberg, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7000 | |
Amy Marie Kaminski, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7000 | |
Ivaldo A Lunardi, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 222 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 Fax: 701-323-5709 |